Sanofi Pays $9.5 Billion to Boost Rare Disease Portfolio with Blueprint Medicines

Sanofi Pays $9.5 Billion To Boost Rare Disease Portfolio With Blueprint Medicines

Hold onto your hats! Sanofi just made a bold move, scooping up Blueprint Medicines for a cool $9.5 billion. This deal is all about rare immunology — the kind of medicine that helps folks with super-rare conditions.

Blueprint’s headliner is Ayvakit (avapritinib), the only FDA-approved treatment for advanced systemic mastocytosis, a rare blood disorder. Sanofi’s eyeing this as a serious power-up for their rare disease lineup, according to the official announcement covered by Reuters.

Here’s the money talk: $129 cash per Blueprint share, totaling around $9.1 billion upfront. There’s a bonus payout of up to $6 per share if regulatory milestones are met — so, the whole thing could hit $9.5 billion. Closing is expected by the end of Q3 2025, once shareholders and regulators give the thumbs up.

Sanofi’s CEO called this a “game-changer” for their rare disease efforts, stacking on previous buys like Vigil Neuroscience and Inhibrx. The acquisition also brings in Blueprint’s promising pipeline, including drugs like elenestinib and BLU-808 — the latter being a nifty oral KIT inhibitor that could play a big role beyond just one rare condition.

This deal isn’t just about adding a trophy drug. It’s Sanofi doubling down on rare diseases with serious impact. Blueprint’s treatments might be niche, but they’re crucial for patients who’ve waited too long for options.

So, keep an eye on this one. Sanofi’s rare immunology portfolio just got a serious upgrade.